Solius Labs Forges a New Health Category with Personalized Sunlight Tech

BAINBRIDGE ISLAND, WA – June 17, 2026 – In a move that signals a significant shift in the landscape of consumer health technology, Solius Labs today launched Solius Pro, the first and only over-the-counter medical device that delivers personalized UVB light therapy. Backed by a fresh $23 million in Series A funding, the company is not merely introducing a new gadget; it is pioneering a new, FDA-recognized category for at-home health, aiming to solve the pervasive problem of insufficient sunlight exposure.

The device, which uses a patented skin analysis system to deliver a precise, five-minute weekly dose of UVB light, represents a durable approach to wellness. It moves beyond temporary fixes, offering a medically validated, long-term strategy for stimulating the body's natural production of vitamin D and other vital compounds, all while navigating the complex intersection of regulatory approval, scientific validation, and consumer accessibility.

A New Horizon in FDA Regulation

The most telling sign of Solius Pro's disruptive potential lies not just in its technology, but in its regulatory journey. The U.S. Food and Drug Administration (FDA) has granted the device clearance as a Class II medical device, a classification for products with a moderate risk that require special controls to ensure safety and effectiveness. Crucially, the FDA also established a completely new product code, SGZ, designating it as an “Ultraviolet lamp product intended to stimulate the production of Vitamin D.”

This is more than bureaucratic alphabet soup. Creating a new product code signifies that the FDA recognizes Solius Pro as a novel technology, distinct from existing phototherapy devices. By clearing it for over-the-counter (OTC) sale, the agency has effectively unlocked a new market for personalized, medical-grade therapies that consumers can access without a prescription. This move lowers the barrier between clinical-grade technology and the individual, a hallmark of the most resilient and value-driven trends in 21st-century healthcare. It suggests a future where individuals are empowered with tools to manage their own health based on precise, personalized data.

The Science of Controlled Sunlight

For decades, the message around sunlight has been one of caution. Solius Labs aims to reframe that conversation by isolating the benefits and engineering out the risks. The company’s core claim is that Solius Pro delivers “12x more UVB biological benefit than the sun with 99% less UV risk.” This is achieved by using a targeted 293-nanometer UVB wavelength, which is highly effective for vitamin D synthesis, while filtering out harmful UVA radiation.

“Decades of peer-reviewed research confirm that sunlight is fundamental to human health beyond vitamin D," said Chris Kiple, Chief Executive Officer of Solius Labs, in a statement. "Solius is the first technology to deliver the health benefits of UVB light therapy with dosing personalized to each user’s skin."

This personalization is the key to its safety profile. A patented skin analysis system uses a sensor to measure a user's unique skin tone, automatically calculating a precise dose to hit the biological sweet spot—enough UVB to trigger positive effects without causing skin damage. Clinical data supports these safety claims. While a randomized controlled trial published in Anticancer Research noted minor, transient adverse events like redness in about half of participants, a separate study by Eurofins Clinical Research Laboratories found that 100% of users received their dose without adverse skin reactions like erythema or edema.

The efficacy is also well-documented. The Anticancer Research study demonstrated that participants using the Solius system saw their vitamin D levels increase by an average of 10.2 ng/mL, a 76% jump from their baseline. This focus on quantifiable, systemic benefits—including potential positive impacts on mood, energy, and immune function—is what separates Solius Pro from the crowded wellness market.

Reshaping the Phototherapy Market

Solius Labs is entering a market historically bifurcated between prescription-grade clinical equipment and low-tech consumer wellness lamps. Traditional phototherapy, offered by companies like Phothera and Solarc Systems, typically requires a physician's prescription and is aimed at treating specific skin conditions like psoriasis. Solius Pro carves out a new niche focused on systemic health for the general consumer.

The company’s strategy and leadership inspire confidence. Under CEO Chris Kiple, who previously scaled ventilator production at Ventec Life Systems in a landmark partnership with General Motors during the pandemic, Solius has demonstrated its own resilience. The company pivoted from its original, larger kiosk-based model to the more accessible and scalable at-home device. The successful $23 million Series A round, led by Lauder Partners, validates this strategic shift and provides the capital to execute its vision.

Priced at $2,995, Solius Pro is positioned as a premium, long-term investment in health. It competes not on price, but on value, safety, and a foundation of clinical evidence. This strategy targets a discerning consumer who understands the difference between a temporary wellness trend and a permanent addition to a resilient health strategy.

From Clinic to Consumer: The User Experience

The device is designed for seamless integration into a weekly routine. The light panel, which can be hung on a wall or door, is controlled by a smartphone app. The user experience is built around safety and simplicity. The app guides the user through the initial skin assessment, calculates the personalized dose, and manages the five-minute session, ensuring protective eyewear is worn and therapy is delivered correctly to the user's back.

Accessibility is further enhanced by its eligibility for purchase using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds through platforms like Truemed, though this often requires a Letter of Medical Necessity to be fully compliant. With over 1,000 pre-orders before launch and strong early reviews for its app, Solius has already demonstrated significant market traction, indicating a strong appetite for technologies that offer control, efficacy, and a scientifically-backed path to better health.